Axitinib in metastatic renal cell carcinoma: patient characteristics and treatment patterns in US community oncology centers

To study patient characteristics and treatment patterns in real-world axitinib use for metastatic renal cell carcinoma.

We conducted a retrospective analysis of second- or third-line axitinib use between 1 January 2012 and 31 October 2014 in 135 metastatic renal cell carcinoma patients using the US Oncology Network database.

Overall, 86.7% had clear cell histology, 57.8% had stage III/IV disease at diagnosis and 55.6% were poor risk by Heng criteria. Median treatment duration was 4.6 months (range: 0.03-35.49); 80.7% initiated axitinib at 5 mg/day twice daily, and 67.4% maintained this dose. Overall, 77.8% discontinued treatment, mainly due to disease progression (50.5%) and toxicity (21.9%).

Axitinib usage patterns were consistent with the National Comprehensive Cancer Network Guidelines(®). Ease of use among community oncologists and patient tolerance are key features of axitinib.

Future oncology (London, England). 2017 May 09 [Epub]

Thomas E Hutson, Xiaolong Jiao, Thomas Wilson, Laura Cisar, Elizabeth A MacLean

US Oncology/McKesson Specialty Health, 10101 Woodloch Forest, The Woodlands, TX 77380, USA., Pfizer Oncology, Pfizer Inc, 235 East 42nd St., New York, NY 10017, USA., Pfizer Outcomes & Evidence, 235 East 42nd St., New York, NY 10017, USA.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe